PL3509624T3 - Sposób wykrywania przeciwciał neutralizujących przeciwko leptynie - Google Patents
Sposób wykrywania przeciwciał neutralizujących przeciwko leptynieInfo
- Publication number
- PL3509624T3 PL3509624T3 PL17849795.4T PL17849795T PL3509624T3 PL 3509624 T3 PL3509624 T3 PL 3509624T3 PL 17849795 T PL17849795 T PL 17849795T PL 3509624 T3 PL3509624 T3 PL 3509624T3
- Authority
- PL
- Poland
- Prior art keywords
- methods
- neutralizing antibodies
- detecting anti
- leptin
- leptin neutralizing
- Prior art date
Links
- 229940039781 leptin Drugs 0.000 title 1
- 230000003472 neutralizing effect Effects 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662393632P | 2016-09-12 | 2016-09-12 | |
| PCT/US2017/051232 WO2018049424A1 (en) | 2016-09-12 | 2017-09-12 | Methods of detecting anti-leptin neutralizing antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3509624T3 true PL3509624T3 (pl) | 2024-03-25 |
Family
ID=61559769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17849795.4T PL3509624T3 (pl) | 2016-09-12 | 2017-09-12 | Sposób wykrywania przeciwciał neutralizujących przeciwko leptynie |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US10775386B2 (pl) |
| EP (2) | EP4283304A3 (pl) |
| JP (2) | JP7139317B2 (pl) |
| CN (1) | CN110139663B (pl) |
| BR (1) | BR112019004715A2 (pl) |
| CA (1) | CA3036551A1 (pl) |
| DK (1) | DK3509624T3 (pl) |
| EA (1) | EA201990720A1 (pl) |
| ES (1) | ES2959990T3 (pl) |
| FI (1) | FI3509624T3 (pl) |
| HR (1) | HRP20231076T1 (pl) |
| HU (1) | HUE063647T2 (pl) |
| MX (1) | MX2019002818A (pl) |
| PL (1) | PL3509624T3 (pl) |
| PT (1) | PT3509624T (pl) |
| RS (1) | RS64850B1 (pl) |
| SI (1) | SI3509624T1 (pl) |
| WO (1) | WO2018049424A1 (pl) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3509624T3 (pl) | 2016-09-12 | 2024-03-25 | Amryt Pharmaceuticals Inc. | Sposób wykrywania przeciwciał neutralizujących przeciwko leptynie |
| CA3104120A1 (en) * | 2018-06-16 | 2019-12-19 | Board Of Regents, The University Of Texas System | Weight loss regimen |
| US12385913B2 (en) | 2018-08-03 | 2025-08-12 | Bristol-Myers Squibb Company | Methods for detecting anti-drug antibodies |
| AU2020275406A1 (en) * | 2019-05-13 | 2021-11-18 | Regeneron Pharmaceuticals, Inc. | Improved competitive ligand binding assays |
| CN111983226A (zh) * | 2020-03-25 | 2020-11-24 | 新加坡国立大学 | SARSr-CoV抗体的检测 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5314804A (en) * | 1992-03-24 | 1994-05-24 | Serim Research Corporation | Test for Helicobacter pylori |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| US6350730B1 (en) | 1994-08-17 | 2002-02-26 | The Rockefeller University | OB polypeptides and modified forms as modulators of body weight |
| US6001968A (en) | 1994-08-17 | 1999-12-14 | The Rockefeller University | OB polypeptides, modified forms and compositions |
| US6429290B1 (en) | 1994-08-17 | 2002-08-06 | The Rockefeller University | OB polypeptides, modified forms and derivatives |
| US5827734A (en) | 1995-01-20 | 1998-10-27 | University Of Washington | Materials and methods for determining ob protein in a biological sample |
| US5521283A (en) | 1995-01-31 | 1996-05-28 | Eli Lilly And Company | Anti-obesity proteins |
| US5554727A (en) | 1995-01-31 | 1996-09-10 | Eli Lilly And Company | Anti-obesity proteins |
| US5559208A (en) | 1995-01-31 | 1996-09-24 | Eli Lilly And Company | Anti-obesity proteins |
| US5691309A (en) | 1995-01-31 | 1997-11-25 | Eli Lilly And Company | Anti-obesity proteins |
| US5552524A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
| US5580954A (en) | 1995-01-31 | 1996-12-03 | Eli Lilly And Company | Anti-obesity proteins |
| US5552522A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
| US5605886A (en) | 1995-01-31 | 1997-02-25 | Eli Lilly And Company | Anti-obesity proteins |
| CA2211664A1 (en) | 1995-01-31 | 1996-08-08 | Eli Lilly And Company | Anti-obesity proteins |
| US5552523A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
| US5532336A (en) | 1995-01-31 | 1996-07-02 | Eli Lilly And Company | Anti-obesity proteins |
| US5594101A (en) | 1995-03-03 | 1997-01-14 | Eli Lilly And Company | Anti-obesity proteins |
| WO1996040912A1 (en) | 1995-06-07 | 1996-12-19 | Amgen Inc. | Ob protein compositions and method |
| IL122718A0 (en) | 1995-06-30 | 1998-08-16 | Lilly Co Eli | Methods for treating diabetes |
| ATE259650T1 (de) | 1995-08-17 | 2004-03-15 | Amgen Inc | Verfahren zur verringerung und zur erhaltung von verringerten blutspiegeln von lipiden mittels zubereitungen von ob-proteinen |
| US6936439B2 (en) | 1995-11-22 | 2005-08-30 | Amgen Inc. | OB fusion protein compositions and methods |
| CA2358862A1 (en) | 1995-11-22 | 1997-05-29 | Amgen Inc. | Methods of increasing lean tissue mass using ob protein compositions |
| US20030040467A1 (en) | 1998-06-15 | 2003-02-27 | Mary Ann Pelleymounter | Ig/ob fusions and uses thereof. |
| AU2670897A (en) | 1996-04-04 | 1997-10-29 | Amgen, Inc. | Fibulin pharmaceutical compositions and related methods |
| WO1998006752A1 (en) * | 1996-08-16 | 1998-02-19 | The Rockefeller University | A leptin binding protein and its use in methods for diagnosing and treating abnormalities of the endogenous leptin pathway |
| JP2001501177A (ja) | 1996-08-30 | 2001-01-30 | アムジエン・インコーポレーテツド | Ｏｂタンパク質受容体をアップレギュレートすることによりｏｂタンパク質に対する個体の感受性を増加させる方法 |
| CA2266585A1 (en) | 1996-09-20 | 1998-03-26 | Hoechst Aktiengesellschaft | Use of leptin antagonists for treating insulin resistance in type ii diabetes |
| CA2275183A1 (en) | 1996-12-20 | 1998-07-02 | Amgen Inc. | Ob fusion protein compositions and methods |
| CN1202862C (zh) | 1997-04-17 | 2005-05-25 | 安姆根有限公司 | 包含具有抗体Fc链的稳定、有活性人OB蛋白的结合物的组合物及方法 |
| JP2002504102A (ja) | 1997-06-06 | 2002-02-05 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | 糖尿病治療のためのレプチン拮抗物質の使用 |
| US6541033B1 (en) | 1998-06-30 | 2003-04-01 | Amgen Inc. | Thermosensitive biodegradable hydrogels for sustained delivery of leptin |
| JP4199421B2 (ja) | 1998-08-10 | 2008-12-17 | アムジエン・インコーポレーテツド | デキストラン−レプチン結合体、医薬組成物および関連方法 |
| EP1118001A1 (en) | 1998-10-02 | 2001-07-25 | Amgen Inc. | Method to determine a predisposition to leptin treatment |
| US6420339B1 (en) | 1998-10-14 | 2002-07-16 | Amgen Inc. | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility |
| ATE323766T1 (de) | 1999-02-12 | 2006-05-15 | Amgen Inc | Glykosylierte leptinzusammensetzungen und zugehörige verfahren |
| WO2002074979A2 (en) * | 2001-03-20 | 2002-09-26 | Ortho-Clinical Diagnostics, Inc. | Expression profiles and methods of use |
| JP2005506994A (ja) | 2001-10-22 | 2005-03-10 | アムジェン インコーポレイテッド | ヒト脂肪組織萎縮症を処置するためのレプチンの使用および該処置のための素因決定方法 |
| WO2004039832A2 (en) | 2002-10-31 | 2004-05-13 | Albany Medical College | Leptin-related peptides |
| EP1575602A2 (en) * | 2002-11-25 | 2005-09-21 | Chiron Corporation | Methods for treating cancer using porimin as a target |
| WO2004078944A2 (en) * | 2003-03-05 | 2004-09-16 | Maine Medical Center Research Institute | Thrombin, soluble jaggedi, and trap and growth of stem cells |
| JP4754352B2 (ja) | 2003-08-29 | 2011-08-24 | 株式会社リバース・プロテオミクス研究所 | タンパク質の固定化方法 |
| DE10353593A1 (de) * | 2003-11-17 | 2005-06-23 | Klinikum der Universität München Großhadern-Innenstadt | Leptinantagonist und Verfahren zur quantitativen Messung von Leptin |
| US7320868B2 (en) | 2004-03-19 | 2008-01-22 | Arieh Gertler | Leptin binding domain compositions and methods thereto |
| US8394765B2 (en) | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
| KR20100098628A (ko) | 2007-11-14 | 2010-09-08 | 아밀린 파마슈티칼스, 인크. | 비만 및 비만 관련 질환 및 장애의 치료 방법 |
| GB201004058D0 (en) | 2010-03-11 | 2010-04-28 | Consiglio Nazionale Ricerche | Diagnostic assay for obesity and related disorders |
| JP2014502252A (ja) | 2010-09-28 | 2014-01-30 | アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー | 作用持続時間が増した改変ポリペプチド |
| US20130266963A1 (en) * | 2011-07-06 | 2013-10-10 | Nestec S.A. | Assay for detecting neutralizing autoantibodies to biologic therapy |
| ES2732475T3 (es) | 2011-07-08 | 2019-11-22 | Aegerion Pharmaceuticals Inc | Polipéptidos modificados por ingeniería genética que tienen una duración potenciada de la acción y una inmunogenicidad reducida |
| EP3063543B1 (en) | 2013-10-31 | 2020-03-11 | Regeneron Pharmaceuticals, Inc. | Competitive ligand binding assay for detecting neutralizing antibodies |
| RU2737719C2 (ru) * | 2015-02-27 | 2020-12-02 | Ионис Фармасьютикалз, Инк. | Модулирование экспрессии аполипопротеина с-iii (аросiii) у пациентов с липодистрофией |
| PL3509624T3 (pl) | 2016-09-12 | 2024-03-25 | Amryt Pharmaceuticals Inc. | Sposób wykrywania przeciwciał neutralizujących przeciwko leptynie |
-
2017
- 2017-09-12 PL PL17849795.4T patent/PL3509624T3/pl unknown
- 2017-09-12 HU HUE17849795A patent/HUE063647T2/hu unknown
- 2017-09-12 HR HRP20231076TT patent/HRP20231076T1/hr unknown
- 2017-09-12 RS RS20231049A patent/RS64850B1/sr unknown
- 2017-09-12 WO PCT/US2017/051232 patent/WO2018049424A1/en not_active Ceased
- 2017-09-12 MX MX2019002818A patent/MX2019002818A/es unknown
- 2017-09-12 EA EA201990720A patent/EA201990720A1/ru unknown
- 2017-09-12 ES ES17849795T patent/ES2959990T3/es active Active
- 2017-09-12 PT PT178497954T patent/PT3509624T/pt unknown
- 2017-09-12 US US15/702,719 patent/US10775386B2/en active Active
- 2017-09-12 EP EP23188153.3A patent/EP4283304A3/en active Pending
- 2017-09-12 EP EP17849795.4A patent/EP3509624B1/en active Active
- 2017-09-12 CN CN201780069880.XA patent/CN110139663B/zh active Active
- 2017-09-12 DK DK17849795.4T patent/DK3509624T3/da active
- 2017-09-12 FI FIEP17849795.4T patent/FI3509624T3/fi active
- 2017-09-12 CA CA3036551A patent/CA3036551A1/en active Pending
- 2017-09-12 SI SI201731435T patent/SI3509624T1/sl unknown
- 2017-09-12 JP JP2019513974A patent/JP7139317B2/ja active Active
- 2017-09-12 BR BR112019004715-8A patent/BR112019004715A2/pt unknown
-
2020
- 2020-08-18 US US16/996,281 patent/US11709166B2/en active Active
-
2022
- 2022-09-07 JP JP2022142227A patent/JP7509834B2/ja active Active
-
2023
- 2023-06-07 US US18/330,550 patent/US20230314447A1/en not_active Abandoned
-
2025
- 2025-01-16 US US19/025,067 patent/US20250155450A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2019002818A (es) | 2019-08-29 |
| HUE063647T2 (hu) | 2024-01-28 |
| JP2019529904A (ja) | 2019-10-17 |
| EP4283304A3 (en) | 2024-02-28 |
| CA3036551A1 (en) | 2018-03-15 |
| PT3509624T (pt) | 2023-08-28 |
| US20180074073A1 (en) | 2018-03-15 |
| CN110139663B (zh) | 2024-05-07 |
| JP7509834B2 (ja) | 2024-07-02 |
| CN110139663A (zh) | 2019-08-16 |
| US20250155450A1 (en) | 2025-05-15 |
| EP4283304A2 (en) | 2023-11-29 |
| US20230314447A1 (en) | 2023-10-05 |
| RS64850B1 (sr) | 2023-12-29 |
| US11709166B2 (en) | 2023-07-25 |
| EA201990720A1 (ru) | 2019-08-30 |
| EP3509624A4 (en) | 2020-02-19 |
| HRP20231076T1 (hr) | 2023-12-22 |
| SI3509624T1 (sl) | 2023-12-29 |
| BR112019004715A2 (pt) | 2019-07-16 |
| EP3509624A1 (en) | 2019-07-17 |
| US10775386B2 (en) | 2020-09-15 |
| WO2018049424A1 (en) | 2018-03-15 |
| ES2959990T3 (es) | 2024-02-29 |
| EP3509624B1 (en) | 2023-08-09 |
| FI3509624T3 (fi) | 2023-10-18 |
| DK3509624T3 (da) | 2023-11-13 |
| JP7139317B2 (ja) | 2022-09-20 |
| US20200378988A1 (en) | 2020-12-03 |
| JP2022176209A (ja) | 2022-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL286853A (en) | Methods for diagnosing sepsis | |
| IL257565A (en) | Improved variants of anti-vegf antibodies | |
| ZA201802543B (en) | Multivalent fv antibodies | |
| IL250415A0 (en) | Antibodies against pd-l1 | |
| SG11201705552QA (en) | Anti-pd-l1 antibodies | |
| ZA202002137B (en) | Methods of detecting transthyretin | |
| SG11201703756RA (en) | Determining timing for determination of applicable geo-fences | |
| PT3458100T (pt) | Redução seletiva de anticorpos modificados por cisteína | |
| IL251440B (en) | Methods and systems for identifying analytes | |
| GB201415761D0 (en) | Methods for detection of Nucleotide modification | |
| IL248391A0 (en) | Methods for using anti-ang2 antibodies | |
| PT3509624T (pt) | Métodos de deteção de anticorpos neutralizantes anti-leptina | |
| GB201515693D0 (en) | Method for antigen detection | |
| GB201703261D0 (en) | Method of detection | |
| GB201617628D0 (en) | Method of determining presence of Isotopes | |
| GB201518675D0 (en) | Detection of structural forms of proteins | |
| GB201414419D0 (en) | Method of testing | |
| GB2553103B (en) | Method of angle detection | |
| PT3105621T (pt) | Método de identificação de sinais refletidos | |
| SG11201704642WA (en) | Method for the detection of hormone sensitive disease progression | |
| GB2553005B (en) | Method of line detection | |
| GB201402195D0 (en) | Method and systejm for determining spatial position of receiving device | |
| SG10201603579PA (en) | Methods Of Detecting Cancer | |
| GB201420375D0 (en) | Method of detecting amp | |
| GB201604600D0 (en) | Determination of relative sensitivities |